BEBartu Ediz

Bartu Ediz

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Bartu Ediz has a total of 123 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Asymptomatic Medullary Thyroid Carcinoma With Isolated Carcinoembryonic Antigen Elevation in a Patient With Chronic Kidney Disease: A Case Report

    by Orhan Altınyüzük, Bartu Ediz, Serkan Feyyaz Yalın, Ergün Parmaksız

    Medullary thyroid carcinoma (MTC) is rare and typically presents with a palpable nodule. We report a 64‐year‐old asymptomatic woman with chronic kidney disease (CKD) diagnosed with MTC after incidental procalcitonin elevation on routine labs, highlighting procalcitonin as an atypical clue and the need to distinguish tumor‐related from CKD‐related hypercalcitoninemia.

  • Open Access

    Serratia marcescens peritonitis in a continuous ambulatory peritoneal dialysis patient: A case report and literature review

    by Orhan Altınyüzük, Melike Hazal Umut, Bartu Ediz, Meral Meşe, Serkan Feyyaz Yalın, Ergün Parmaksız

  • Open Access

    Etelcalcetide Versus Cinacalcet for Secondary Hyperparathyroidism in Hemodialysis Patients: A Multicentre Comparison with 24 Months of Follow-Up

    by Hakkı Öztürk, Çiğdem Ikhlef, Berrak Itır Aylı, Veysel Baran Tomar, Bartu Ediz, Ebru Gök Oğuz, Elif Arı Bakır, Galip Güz, Mehmet Deniz Aylı

    Background/Objectives: Secondary hyperparathyroidism (SHPT) is a prevalent complication of end-stage kidney disease. Although etelcalcetide has demonstrated short-term superiority over cinacalcet in randomized trials, real-world comparative data beyond 12 months remain scarce. This study compared the long-term effectiveness of etelcalcetide versus cinacalcet in hemodialysis patients over 24 months using propensity score matching. Methods: This multicenter retrospective study screened 457 hemodialysis patients across five centers in Türkiye. Propensity score matching on age, sex, hemodialysis vintage, and baseline intact parathyroid hormone (iPTH) yielded balanced cohorts of 21 versus 21 for 12-month and 14 versus 14 for 24-month analyses. The primary outcome was percentage change in iPTH from baseline (%ΔPTH). Secondary outcomes included responder rates, KDIGO target achievement, response trajectory classification, and depth-of-response analysis. Results: At 12 months, etelcalcetide achieved significantly greater iPTH reduction (%ΔPTH: −50.5 ± 25.6% vs. −29.7 ± 40.6%; p = 0.047), with effect sizes increasing from medium to medium–large at 24 months (Cohen’s d: −0.612 to −0.779). Sustained response (≥30% iPTH reduction at both timepoints) was significantly higher with etelcalcetide (78.6% vs. 28.6%; p = 0.021), as was deep response (≥75% reduction) at 24 months (57.1% vs. 14.3%; p = 0.046). At 24 months, etelcalcetide demonstrated significantly lower serum calcium (p = 0.015), calcium–phosphate product (p = 0.023), and superior phosphate target attainment (85.7% vs. 28.6%; p = 0.004). Inter-patient response variability was nearly three-fold lower with etelcalcetide (CV: 42% vs. 151%). Conclusions: Etelcalcetide provided significantly greater, more sustained, and more consistent iPTH suppression than cinacalcet over 24 months, with additional benefits in mineral metabolism control. These findings support etelcalcetide as a potent therapeutic option for SHPT in hemodialysis patients and warrant confirmation in larger prospective trials.

  • Open Access

    Real-world epidemiology and renal outcomes of ADPKD in Türkiye: the PKD-TURK cohort

    by Serpil Muge Deger, Necmi Eren, Sibel Yucel Kocak, Gulay Ulusal Okyay, Beyhan Güvercin, Abdulmecit Yildiz, Halime Soyak Kabaca, Sabahat Alisir Ecder, Tahsin Karaaslan, Ayca Inci, et al.

    Introduction: Real-world epidemiological and longitudinal outcome data on autosomal dominant polycystic kidney disease (ADPKD) remain limited in underrepresented populations, including Türkiye. We aimed to characterize the epidemiology, regional distribution, and renal outcomes of ADPKD in a large multicenter national cohort. Methods: In this retrospective multicenter study, adult patients with ADPKD were identified across tertiary nephrology centers in six regions of Türkiye (2010–2025). Study-based prevalence was calculated using Turkish Statistical Institute population data. Longitudinal renal outcomes were evaluated using serial eGFR measurements and Cox regression models identified predictors of ≥ 40% eGFR decline. Results: A total of 2361 patients were included (mean age 38.6 ± 14 years; 51.8% female). Median province-level study-based prevalence was 3.86 per 100,000 population (IQR 2.92–5.49), with substantial regional variation, highest in the Black Sea region (13.46 per 100,000). Study-based prevalence increased significantly over time (annual percent change 14.4%; 95% CI 13.1–15.6; p < 0.001). During a median follow-up of 6 years, 23.9% experienced a ≥ 40% eGFR decline and 10.5% progressed to kidney failure (eGFR < 15 ml/min/1.73m2). Median annual eGFR decline was − 3.33 mL/min/1.73 m²/year. In multivariable analysis, age (adjusted HR 1.02; 95% CI 1.00–1.03; p = 0.010) and hypertension (adjusted HR 2.33; 95% CI 1.25–4.32; p = 0.007) were independently associated with renal progression, whereas tolvaptan use was associated with a lower risk of progression (adjusted HR 0.56; 95% CI 0.37–0.85; p = 0.004). The Mayo Imaging Classification remained independently predictive of renal outcomes (p = 0.027). Conclusions: This large real-world multicenter cohort highlights the geographically heterogeneous study-based burden of ADPKD across participating regions of Türkiye. Increasing prevalence over time likely reflects improved disease recognition, whereas the relatively low study-based prevalence suggests persistent under-recognition of ADPKD. These findings provide important longitudinal outcome data from an underrepresented population and support the need for earlier detection and improved risk stratification in ADPKD.

  • Open Access

    Hyperkalemia Risk After Finerenone Initiation in Diabetic Kidney Disease with Elevated Baseline Potassium: A Multicenter Cohort Study

    by Alper Tuna Güven, Serap Yadigar, Murat Özdede, Suat Akgür, Felemez Arslan, Mehmet Sezen, Büşra Özcan, Elif Yıldırım Ayaz, Betül Doğantekin, İlker Atay, et al.

    Background/Objectives: Finerenone improves cardiovascular and renal outcomes in diabetic kidney disease (DKD), but hyperkalemia remains a key safety concern. Patients with elevated baseline potassium levels (≥4.9 mEq/L) are largely excluded from clinical trials, and real-world data in this population are scarce. Methods: In this retrospective multicenter cohort study derived from the FINE-TURK cohort, adults with DKD who initiated finerenone with baseline potassium ≥ 4.9 mEq/L were included. The primary outcome was clinically significant hyperkalemia (K ≥ 5.5 mEq/L) within three months. Multivariable logistic regression analyses were used to identify associated factors, with multiple sensitivity analyses performed. Results: A total of 166 patients were included, of whom 47 (28.3%) had baseline potassium levels between 5.1 and 5.5 mEq/L. Of the 166 patients, 35 (21.1%) reached the primary outcome, and 10 (6%) patients had follow-up potassium ≥ 6.0 mEq/L. 126 (76.8%) patients required no intervention, 24 (14.6%) were initiated on potassium binders, and finerenone was discontinued in only 12 (7.3%) patients. Lower baseline estimated glomerular filtration rate, baseline urinary albumin, loop diuretic use and 20 mg finerenone dose were associated with the primary outcome. In contrast, baseline potassium was not associated with the primary outcome. Conclusions: In patients with DKD and elevated baseline potassium levels, finerenone initiation was associated with manageable rates of hyperkalemia. Our findings support the cautious use of finerenone in selected patients under close monitoring, as well as highlight the need for a multidimensional approach to hyperkalemia risk assessment.

  • Open Access

    Hyperkalemia Risk and Associated Factors After Finerenone Initiation in Patients with Diabetic Kidney Disease and Elevated Baseline Potassium: A Real-World Cohort Study

    by Alper Tuna Güven, Serap Yadigar, Murat Özdede, Suat Akgür, Felemez Arslan, Mehmet Sezen, Büşra Özcan, Elif Yıldırım Ayaz, Betül Doğantekin, İlker Atay, et al.

    Background/Objectives: Finerenone improves cardiovascular and renal outcomes in diabetic kidney disease (DKD), but hyperkalemia remains a key safety concern. Patients with elevated baseline potassium levels (≥ 4.9 mEq/L) are largely excluded from clinical trials, and real-world data in this population are scarce. Methods: In this retrospective multicenter cohort study derived from the FINE-TURK cohort, adults with DKD who initiated finerenone with baseline serum potassium ≥ 4.9 mEq/L were included. The primary outcome was clinically significant hyperkalemia (CSH) (≥ 5.5 mEq/L) within three months. Multivariable logistic regression analyses were used to identify associated factors, with multiple sensitivity analyses performed. Results: 166 patients were included, of whom 47 (28.3%) had baseline potassium levels between 5.1 to 5.5 mEq/L. Of the 166 patients, 35 (21.1%) developed CSH, and 10 (6%) patients had follow-up potassium ≥ 6.0 mEq/L. 126 (76.8%) patients required no intervention, 24 (14.6%) were initiated on potassium binders, and finerenone was discontinued only in 12 (7.3%) patients. Baseline eGFR, baseline urinary albumin, loop diuretic use and 20mg finerenone dose were associated with CSH. In contrast, baseline serum potassium was not associated with CSH. Conclusions: In patients with DKD and elevated baseline potassium levels, finerenone initiation was associated with manageable rates of hyperkalemia. Our findings support the cautious use of finerenone in selected patients under close monitoring, as well as highlight the need for a multidimensional approach to hyperkalemia risk assessment.

  • Open Access

    Hyperkalemia Risk with Finerenone in Diabetic Kidney Disease: A Real-World Analysis from the FINE-TURK Cohort

    by Murat Özdede, Serap Yadigar, Alper Tuna Güven, Suat Akgür, Felemez Arslan, Mehmet Sezen, Büşra Özcan, Elif Yıldırım Ayaz, Betül Doğantekin, İlker Atay, et al.

    Background: Finerenone is associated with a lower, yet clinically relevant, risk of hyperkalemia compared with steroidal mineralocorticoid receptor antagonists in diabetic kidney disease (DKD) trials. However, real-world data on hyperkalemia and its associated factors are lacking. Methodology: FINE-TURK is a national, observational cohort of DKD patients who were initiated on finerenone. Eligible adults were included; demographic, clinical, and laboratory data were evaluated. The primary outcome (PO) was hyperkalemia risk signal (potassium ≥ 5.0 mEq/L), and the secondary outcome (SO) was clinically meaningful hyperkalemia (potassium ≥ 5.5 mEq/L). Multivariate logistic regression (LR) was used to define features associated with both PO and SO. LR, random forest (RF), gradient boosting, and CatBoost classifiers were used to define important features associated with the PO. Results: 699 patients were included. 259 (37.1%) reached the PO, and 51 (7.3%) reached the SO. Baseline potassium and estimated glomerular filtration rate (eGFR) were the most important variables associated with both outcomes and were consistently identified as the top features across all models. Thiazide use, presence of diabetic retinopathy, and diabetes duration were also associated with the PO. LR demonstrated the highest recall; random forest achieved the highest precision in performance. Discussion: Real-world data suggest that the risk of clinically meaningful hyperkalemia is similar to that in the clinical trials. In parallel with the safety analysis of clinical trials, baseline potassium and eGFR were consistently the most important factors associated with hyperkalemia risk.